Completed PHASE2 INTERVENTIONAL NCT00336466

The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS)

The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS): A Randomized, Double-Blind, Placebo Controlled Proof-of-Concept Clinical Trial.

Sponsor: Calgary Health Region

Conditions Brain Injury Cardiac Surgery

Interventions Human recombinant erythropoietin

Updated 5 times since 2017 Last updated: Nov 26, 2007 Started: Sep 30, 2004 Completion: May 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Brain Injury and Cardiac Surgery, this trial is completed. The trial is conducted by Calgary Health Region and has accumulated 5 data snapshots since 2004. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Calgary Health Region
Ortho Biotech, Inc.
University of Calgary

Data source: University of Calgary

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Calgary, Canada